Under the supervision of Nippon Petrochemical (Osaka,
Japan), N-aspartyl chlorin e6 (NPe6) is being studied
as a possible photosensitizer for PDT .
Phase I clinical trials are under way for the treatment of
cutaneous malignancies and it is also being investigated
in Japan as a possible therapy for endobronchial lung cancer.
Npe6 has been shown to be an effective photosensitizer
against skin cancers with little or no long-term cutaneous
The photodynamic activity of
Npe6 also involves a combination of vascular (indirect
effect) and direct anti-tumour photodamage, which is
another potential advantage of this photosensitizer.